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Artificial Organs: SynCardia Heart
Kaity Keesling
Abstract: With an increased prevalence of cardiovascular disease, heart transplants are on the rise. As a result, the need for donor hearts
exceeds current availability. To care for heart failure patients, healthcare professionals have developed the SynCardia total artificial heart.
This article explains the artificial heart and its implementation into clinical practice.

A

pressing public health issue currently affecting the United
States is the rising prevalence of heart disease. This illness
accounted for over 600,000 deaths in 2016, placing heart
disease as the leading cause of death in the nation.1 While the
demand for heart transplants grows in response to increasing
disease prevalence, the availability of donor organs remains
unchanged. This disparity between supply and demand has led
medical professionals to seek solutions elsewhere. An alternative
for patients in need of a new organ is the utilization of artificial
organs. An artificial organ is any human made machine, device,
tissue or other material that is used to replace the functions of an
organ in the human body.2 In order to combat the high mortality
rates related to heart disease, the total artificial heart (TAH) was
developed. This device is a pump that is surgically inserted to
replace diseased or damaged heart ventricles and provide
circulation.3 Although the artificial heart is not a permanent
solution, it buys patients time until they receive a heart transplant.
The growing prevalence of heart disease has created an imbalance
between availability and need of donor organs. However, the
artificial heart serves as a lifesaving solution for patients awaiting
a transplant.
As heart disease continues to rise and cause health complications,
the number of people waiting for a new heart has increased as well.
To date, there are over 3,700 people on the heart transplant
waiting list, which drastically exceeds organ availability.4 For those
in need of a transplant, the waiting time is often long because the
donor heart must be similar in size and blood type. This long
waiting period can be extremely difficult to endure, especially for
those in end stage heart failure. The low donor availability
combined with unfavorable heart health conditions continues to
split the gap between organ supply and demand, encouraging
medical professionals to seek alternative care options.
Artificial organs were developed to meet the high demand for
organ transplants. Artificial organs vary greatly, depending on the
structure and function they are intended to replace. While many
artificial organs are completely synthetic, others are grown in a lab.
Lab grown organs use stem cells to regenerate, repair, or replace
damaged tissue or whole organs.5 Potential advantages of lab
grown organs include reduced likelihood of transplant rejection
and permanent replacement of the faulty organ or tissue. Still,
complex organs such as the heart are difficult to produce in this
manner.5 Due to its size and complexity, stem cells are unable to
generate a fully functioning, adult-sized heart. Instead, artificial
hearts are made from biocompatible plastic. This type of plastic
minimizes the likelihood of rejection so that the body is more likely
to accept the artificial organ.

The first recorded artificial heart transplant performed on a
human occurred in 1982 using the Jarvik-7 model heart.6 Today,
the Total Artificial Heart (TAH) by SyCardia is the only FDA
approved fully synthetic heart that is designed for use as a
temporary bridge to live organ transplant.7 It is a pump that is
surgically installed to provide circulation and replace heart
ventricles that are diseased or damaged. The structure of the
synthetic heart closely mimics that of a natural, live heart. 8 The
TAH contains two artificial ventricles made from biocompatible
plastic. The two ventricles are connected in the middle by velcro,
which allows unique positioning and placement of the heart
depending on the anatomy of each individual patient. An
external machine performs the pumping action rather than live
muscle tissue.8
Within each ventricle in the artificial heart are two valves, one for
inflow and one for outflow, which control the movement of
blood in and out of the heart.8 There is also a flexible diaphragm
membrane which splits each ventricle into two chambers, one for
air and one for blood. The formation of these two areas helps the
external pumping system control blood flow by inflating and
deflating portions of the heart in a regular pattern. The tubes that
connect the internal artificial heart to the external system that
regulates blood flow are called cannulae. These tubes are
partially covered in velour fabric, similar to a plush velvet,
promoting proper healing at the tube exit site through the
abdominal wall. The cannulae connect further to two additional
external tubes called drivelines which connect to the external
pumping system.8
Along with the artificial heart on the interior of the body, external
drivers, which act as the battery pumping the heart, are equally
necessary. There are various types of external drivers that serve
different purposes, depending on the situation and needs of the
patient. Some external pumping systems are portable while
others are not, but each work in a similar way. The machine
produces pulses of air and vacuum in order to inflate and deflate
the diaphragms which push blood in and out of the ventricles.8
In 2004, the CCS driver was approved for medical use, followed
by the C2 driver in 2012. Although effective and serve their
intended purpose, these batteries limit patient freedom since
they are used in a stationary position, typically in a hospital.7 A
new model called the Freedom Driver was FDA approved in 2014,
granting freedom of movement to patients who received a total
artificial heart.7 Patients can be switched to this lighter, portable
battery and sent home once they are clinically stable. The
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minimal maintenance and ease of use allow patients to lead a
nearly normal lifestyle while waiting for a donor heart.
Since its approval, the SynCardia heart has been implanted over
1300 times in the United States, Canada, and Europe. 9 As a result,
total artificial heart transplants have dramatically improved the
‘bridge to transplant’ survival period from 46% to >79%.10 The
limitations to its efficacy include durability and length of time the
artificial heart can remain in a person’s body without causing
secondary complications. The longest known usage of the
SynCardia total artificial heart is currently 4.6 years or
approximately 1700 days.11 Since it’s not a permanent solution to
poor heart health, an artificial heart is only indicated to sustain life.
Criteria to meet eligibility requirements for a TAH are very
specific.12 First, a patient must be suffering from very advanced or
end stage heart failure. Both sides of the heart (biventricular) must
also be affected. Lastly, patients must be eligible or likely to
become eligible for a heart transplant. Since heart failure is
irreversible, the TAH is the greatest chance for survival until a
donor heart becomes available.12 However, it comes at a high cost.
The estimated cost of a TAH is about $150,000 without insurance,
though this cost may differ depending on who performs the
transplant.10 Despite this high price tag, most insurance companies
will cover the majority of expenses. There is little to no cost for
upkeep of the synthetic heart, although there is some maintenance
work to ensure its continued efficacy.
In response to the growing prevalence and mortality related to
heart disease, the United States has a growing disparity between
the need and supply of donor organs available for transplant. The
excess demand for life-saving intervention has led to the
development of a wide variety of artificial organs. While many of
these devices are not intended for permanent use, like the
SynCardia total artificial heart, they are effective at bridging
patients to transplant of a live organ. The future of artificial organs
is promising, as more effective treatment options are being
developed, allowing for increased quality of patient care as
synthetic organs help to sustain life.
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